HeartBeam’s ALIGN-ACS Results Signal Potential Shift in Remote Heart Attack Assessment

HeartBeam’s positive ALIGN-ACS pilot study results show its portable ECG technology achieved higher specificity than standard ECGs for heart attack assessment, supporting a planned U.S. pivotal trial and potential FDA submission.

Chicago Metrowire Staff
••Healthcare
HeartBeam’s ALIGN-ACS Results Signal Potential Shift in Remote Heart Attack Assessment

HeartBeam Inc. (NASDAQ: BEAT) reported positive results from its ALIGN-ACS pilot study, demonstrating that its portable, cable-free electrocardiogram (ECG) technology could improve the assessment of acute coronary syndrome (ACS) outside traditional clinical settings. The findings, presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego, are significant because they suggest a patient-operated device may eventually help differentiate cardiac chest pain more accurately than standard 12-lead ECGs, potentially accelerating triage and reducing unnecessary hospitalizations.

The study enrolled 132 adults and compared HeartBeam’s 3D ECG system with conventional 12-lead ECGs. HeartBeam achieved higher specificity (81.8% versus 71.4%) while maintaining comparable sensitivity (60.2% versus 63.0%). For ST-elevation myocardial infarction (STEMI), sensitivity was 82.9% for HeartBeam versus 83.8% for standard ECGs. Notably, all participants successfully recorded their own ECGs under clinical supervision without prior training, underscoring the device’s ease of use. The study also found greater consistency among cardiologists interpreting HeartBeam recordings, which could reduce variability in remote cardiac assessments.

These results matter because heart attacks remain a leading cause of death, and timely, accurate diagnosis is critical. A portable, cable-free ECG that patients can use themselves could extend diagnostic capability beyond hospitals and clinics, enabling earlier intervention. For HeartBeam, the data support its plan to launch a U.S. pivotal study in the first quarter of 2027, aiming to expand the system’s indication beyond arrhythmia assessment to include heart attack assessment. The technology already holds FDA Breakthrough Device Designation for heart attack assessment, but it remains investigational and is not currently FDA-cleared for that use. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025.

Investors and industry observers can view the full press release at https://ibn.fm/8QTjB and access the company’s latest newsroom updates at https://ibn.fm/BEAT. Detailed information on the cleared indications for use is available at https://www.heartbeam.com/indications.

HeartBeam is focused on transforming cardiac monitoring with its cable-free device that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG. This platform is designed for portable use wherever the patient is, delivering actionable heart intelligence that could redefine cardiac health management. The ALIGN-ACS pilot study reinforces the potential of this approach to improve diagnostic accuracy and consistency, though further clinical validation is needed.

The announcement was distributed through MissionIR, a communications platform that is part of the Dynamic Brand Portfolio at IBN. MissionIR provides syndicated content to enhance visibility for private and public companies, utilizing services such as InvestorWire for wire distribution and editorial syndication to 5,000+ outlets. For more information, visit MissionIR.

Blockchain Registration

QR Code for Blockchain Registration